Keyphrases
COVID-19
100%
Herpes Simplex Virus
63%
Pediatric
44%
Pharmacokinetics
43%
Pediatric Patients
37%
Herpes Simplex Virus 2 (HSV-2)
36%
Children with Obesity
34%
Solid Organ Transplant Recipients
28%
Herpesvirus Entry Mediator
27%
Physiologically-based Pharmacokinetic Model
25%
Neonatal Herpes
25%
Herpes Simplex Virus Type 1 (HSV-1)
24%
Nirsevimab
24%
Obesity
20%
Respiratory Syncytial Virus
19%
Pediatric Transplantation
19%
Pediatric Population
19%
Invasive Candidiasis
19%
Herpes Simplex Virus Encephalitis
18%
Hospitalized children
18%
Infectious Diseases Society of America
18%
Herpes Simplex Virus Infection
15%
United States
15%
Confidence Interval
14%
Risk Factors
14%
Neurological Diseases
14%
Population Pharmacokinetic Model
14%
Neonate
14%
Population Pharmacokinetics
14%
Entry Receptor
14%
Infection Diagnosis
14%
Immunocompromised Pediatric Patients
14%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
13%
COVID-19 Pandemic
13%
Cytomegalovirus
13%
Nectin-1
13%
Mouse Model
12%
Diagnostic Test
12%
Virus
12%
Neurological Manifestations
12%
Metagenomic Next-generation Sequencing (mNGS)
12%
Multisystem Inflammatory Syndrome in children (MIS-C)
12%
Returns to Schooling
12%
Haematopoietic Stem Cell Transplant Recipients
12%
Multicenter Prospective Study
12%
Levetiracetam
12%
Single Center
12%
HIV-infected children
12%
High-frequency Jet Ventilation
12%
Sensory Irritation
12%
Medicine and Dentistry
Pediatrics
93%
Infection
68%
Severe Acute Respiratory Syndrome Coronavirus 2
60%
COVID-19
56%
Herpes Simplex Virus
32%
Diseases
29%
Infectious Disease
28%
Neonatal Infant
25%
Pediatrics Patient
23%
Human Immunodeficiency Virus
20%
Virus Infection
18%
Neurologic Disease
18%
Pediatric Infection
14%
Childhood Cancer
14%
Virus
14%
Odds Ratio
13%
Omicron Coronavirus Variant
13%
Systemic Candidiasis
12%
Prevalence
12%
Aciclovir
12%
Next Generation Sequencing
12%
Serositis
12%
Cytomegalovirus
12%
Messenger RNA
12%
Cohort Analysis
12%
Neurologic Finding
10%
Clinical Trial
10%
Neonatal Herpes Simplex
10%
Central Nervous System
10%
Immunogenicity
9%
Solid Organ Transplantation
9%
Human Immunodeficiency Virus Infection
9%
Antiretroviral Therapy
9%
Public Health
8%
Zika Virus
8%
Herpes Simplex Encephalitis
8%
Valganciclovir
8%
Host Pathogen Interaction
8%
Stem Cell
8%
Antifungal Therapy
8%
Combination Therapy
7%
Cytomegalovirus Infection
7%
Immune Response
7%
Pandemic
7%
Whole Genome Sequencing
7%
Liver Graft
7%
Masking
7%
Herpes Simplex Virus 2
7%
Stem Cell Transplant
7%
Immunocompromised Patient
7%